The stock's rise snapped a five-day losing streak.

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

For the biopharma industry to match the pace of genomic innovations and speed new therapies to market, it will need to ...

Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...

Albany County Executive Dan McCoy presented his $847 million executive budget proposal Monday. “This is a great budget for ...

Regeneron Pharmaceuticals (REGN) said it currently expects that financial results for the third quarter 2024 will include an acquired ...

Breast cancer is the most common form of the disease diagnosed among women in the United States and decades of work in education, research and treatment played an ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing ...

Regeneron Pharmaceuticals expects to book a $56 million pretax charge related to collaboration and licensing agreements. The Westchester County, New York-based biotechnology company said Monday it ...

Regeneron Pharmaceuticals expects to book a $56 million pretax charge related to collaboration and licensing agreements. The Westchester County, New York-based biotechnology company said Monday it ...